Document Detail


Optimizing the approach to anemia in the preterm infant: is there a role for erythropoietin therapy?
MedLine Citation:
PMID:  9280091     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To define a subset of very low birth weight (VLBW) infants who might benefit from recombinant human erythropoietin (r-HuEPO) treatment. STUDY DESIGN: We reviewed the records for all VLBW (birth weight (BW) < or = 1500 gm) infants who were admitted to our nursery within the first 3 days of life between January 1991 and December 1994 and discharged alive. RESULTS: These infants received an average of 2.02 transfusions, far fewer than the 7 to 11 previously reported for VLBW infants. Infants with a BW of 1251 to 1500 gm received very few transfusions. More than three quarters of transfused infants received a transfusion in the first 2 weeks of life before r-HuEPO would be expected to be effective. Assigning units to individual infants and holding the units for 14 days, a practice adopted in our blood bank in 1993, resulted in a 44% decrease in donor exposures in infants receiving more than one transfusion. Holding assigned units for 30 days, a practice our blood bank has now adopted, should result in 56% of all transfused infants having a single donor exposure and 89% having one or two donor exposures. Cost-benefit analysis only supports routine use of r-HuEPO in infants weighing less than 750 gm. CONCLUSION: VLBW infants receive far fewer transfusions than the number previously reported. Assigning units to individual patients and holding those units for 30 days, together with efforts to minimize the need for transfusions make routine use of r-HuEPO unnecessary.
Authors:
J Asch; J F Wedgwood
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of perinatology : official journal of the California Perinatal Association     Volume:  17     ISSN:  0743-8346     ISO Abbreviation:  J Perinatol     Publication Date:    1997 Jul-Aug
Date Detail:
Created Date:  1997-10-09     Completed Date:  1997-10-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8501884     Medline TA:  J Perinatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  276-82     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Robert Wood Johnson School of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / therapy*
Blood Transfusion
Erythropoietin, Recombinant / therapeutic use*
Humans
Infant, Low Birth Weight / blood
Infant, Newborn
Infant, Premature / blood*
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maternal and paternal risk factors and adverse neonatal outcomes among Hispanic subgroups in Illinoi...
Next Document:  Parental factors influencing patterns of prenatal care utilization.